Trial
NCT07172867
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Halia Therapeutics, Inc.
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
HT-6184
Why stopped
Business decision to move away from this indication with this intervention, and low enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-25